Accessibility Menu
Arrow-Thin-Down
S&P 500
6,851.97
+0.2%
+11.77
Arrow-Thin-Down
DJI
47,336.68
-0.5%
-226.19
Arrow-Thin-Down
NASDAQ
23,834.72
+0.5%
+109.77
Arrow-Thin-Down
Bitcoin
$103,713.00
-3.4%
-$3,610.08
Arrow-Thin-Down
AAPL
$269.05
-0.5%
-$1.32
Arrow-Thin-Down
AMZN
$254.00
+4.0%
+$9.78
Arrow-Thin-Down
GOOG
$284.03
+0.8%
+$2.21
Arrow-Thin-Down
META
$637.51
-1.7%
-$10.84
Arrow-Thin-Down
MSFT
$517.03
-0.2%
-$0.78
Arrow-Thin-Down
NVDA
$206.73
+2.1%
+$4.24
Arrow-Thin-Down
TSLA
$468.47
+2.6%
+$11.91
Daily Stock GainersDaily Stock LosersMost Active Stocks

Pfizer: Value Play or Past Its Prime?

By Motley Fool YouTube – Mar 27, 2025 at 7:00PM

Explore the exciting world of Pfizer (PFE +0.04%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of Feb. 19, 2025. The video was published on March 27, 2025.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services